Literature DB >> 10915108

Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.

A J Krentz, C J Bailey, A Melander.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10915108      PMCID： PMC1118256          DOI： 10.1136/bmj.321.7256.252

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  11 in total

1.  Information on thiazolidinediones.

Authors:  S M Wolfe; P Lurie; L D Sasich; E Barbehenn
Journal:  Lancet       Date:  2000-07-15       Impact factor: 79.321

2.  The rise and fall of troglitazone.

Authors:  C J Bailey
Journal:  Diabet Med       Date:  2000-06       Impact factor: 4.359

Review 3.  Thiazolidinediones: a new class of antidiabetic drugs.

Authors:  C Day
Journal:  Diabet Med       Date:  1999-03       Impact factor: 4.359

Review 4.  Insulin resistance.

Authors:  A J Krentz
Journal:  BMJ       Date:  1996-11-30

5.  Diabetes: a time for excitement-and concern. Hopeful signs exist that the ravages of diabetes can be tamed.

Authors:  T Orchard
Journal:  BMJ       Date:  1998-09-12

Review 6.  Banting lecture 1988. Role of insulin resistance in human disease.

Authors:  G M Reaven
Journal:  Diabetes       Date:  1988-12       Impact factor: 9.461

Review 7.  The perils of portliness: causes and consequences of visceral adiposity.

Authors:  C T Montague; S O'Rahilly
Journal:  Diabetes       Date:  2000-06       Impact factor: 9.461

8.  Thiazolidinediones: an update.

Authors:  K Schoonjans; J Auwerx
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

9.  Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus.

Authors:  J Eriksson; A Franssila-Kallunki; A Ekstrand; C Saloranta; E Widén; C Schalin; L Groop
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

10.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321
View more
  15 in total

1.  Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4.

Authors:  N B Glazer; W W Cheatham
Journal:  BMJ       Date:  2001-01-27

2.  Is cytochrome modulation the new frontier for decreasing the risk of cataract?

Authors:  Kavitha S Nair; Kirti V Patel; Tejal R Gandhi
Journal:  Indian J Pharmacol       Date:  2009-04       Impact factor: 1.200

3.  Reimbursement of glitazones in treatment of type 2 diabetes patients in Denmark in the context of a voluntary system for submitting pharmacoeconomic studies.

Authors:  Hindrik Vondeling; Peter Bindslev Iversen
Journal:  Eur J Health Econ       Date:  2004-10

4.  Rosiglitazone: trials, tribulations and termination.

Authors:  Andrew J Krentz
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

Review 5.  Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.

Authors:  Sophie Beale; Adrian Bagust; Arran T Shearer; Alan Martin; Lisa Hulme
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 6.  Oral Hypoglycemic Agents in pregnancy: An Update.

Authors:  Nagandla Kavitha; Somsubhra De; Sachchithanantham Kanagasabai
Journal:  J Obstet Gynaecol India       Date:  2013-03-27

Review 7.  Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity.

Authors:  S Giannini; M Serio; A Galli
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

Review 8.  Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Authors:  Andrew J Krentz; Clifford J Bailey
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  Disruption of inducible 6-phosphofructo-2-kinase impairs the suppressive effect of PPARγ activation on diet-induced intestine inflammatory response.

Authors:  Xin Guo; Honggui Li; Hang Xu; Vera Halim; Laura N Thomas; Shih-Lung Woo; Yuqing Huo; Y Eugene Chen; Joseph M Sturino; Chaodong Wu
Journal:  J Nutr Biochem       Date:  2012-07-26       Impact factor: 6.048

Review 10.  New drugs for type 2 diabetes mellitus: what is their place in therapy?

Authors:  Andrew J Krentz; Mayank B Patel; Clifford J Bailey
Journal:  Drugs       Date:  2008       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.